| Harnessing the properties of cobalt coordination complexes for biological application AK Renfrew, ES O'Neill, TW Hambley, EJ New Coordination Chemistry Reviews 375, 221-233, 2018 | 133 | 2018 |
| Combination Strategies to Improve Targeted Radionuclide Therapy TG Chan, E O’Neill, C Habjan, B Cornelissen Journal of Nuclear Medicine 61 (11), 1544-1552, 2020 | 64 | 2020 |
| Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy E O’Neill, V Kersemans, PD Allen, SYA Terry, JB Torres, M Mosley, ... Journal of Nuclear Medicine 61 (5), 743-750, 2020 | 48 | 2020 |
| Hypoxia-Responsive Cobalt Complexes in Tumor Spheroids: Laser Ablation Inductively Coupled Plasma Mass Spectrometry and Magnetic Resonance Imaging Studies ES O’Neill, A Kaur, DP Bishop, D Shishmarev, PW Kuchel, SM Grieve, ... Inorganic Chemistry 56 (16), 9860-9868, 2017 | 38 | 2017 |
| Reversible magnetogenic cobalt complexes ES O'Neill, JL Kolanowski, GH Yin, KM Broadhouse, SM Greive, ... RSC Advances 6 (36), 30021-30027, 2016 | 23 | 2016 |
| 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α-and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma S Poty, K Mandleywala, E O'Neill, JC Knight, B Cornelissen, JS Lewis Theranostics 10 (13), 5802, 2020 | 21 | 2020 |
| [123I] CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer CY Chan, Z Chen, F Guibbal, G Dias, G Destro, E O’Neill, M Veal, D Lau, ... Journal of Nuclear Medicine 64 (12), 1965-1971, 2023 | 17 | 2023 |
| Imaging PARP with [18F]rucaparib in pancreatic cancer models CY Chan, Z Chen, G Destro, M Veal, D Lau, E O’Neill, G Dias, M Mosley, ... European Journal of Nuclear Medicine and Molecular Imaging 49 (11), 3668-3678, 2022 | 16 | 2022 |
| Imaging DNA damage response by γH2AX in vivo predicts treatment response to Lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome E O'Neill, M Mosley, B Cornelissen Theranostics 13 (4), 1302, 2023 | 10 | 2023 |
| Drawing on biology to inspire molecular design: a redox-responsive MRI probe based on Gd (iii)-nicotinamide M Harris, JL Kolanowski, ES O’Neill, C Henoumont, S Laurent, ... Chemical Communications 54 (92), 12986-12989, 2018 | 10 | 2018 |
| A cobalt (ii) complex with unique paraSHIFT responses to anions ES O’Neill, JL Kolanowski, PD Bonnitcha, EJ New Chemical Communications 53 (25), 3571-3574, 2017 | 9 | 2017 |
| Preclinical evaluation of a novel radioligand therapy for patients with prostate cancer: biodistribution and efficacy of 177Lu-rhPSMA-10.1 in comparison with 177Lu-PSMA-I&T C Foxton, R Grønlund, J Simon, B Cornelissen, E O'Neill, R Bejot, ... Journal of Nuclear Medicine 63 (supplement 2), 2567-2567, 2022 | 5 | 2022 |
| Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy E O'Neill, B Cornelissen Nuclear Medicine and Biology 108, 44-53, 2022 | 4 | 2022 |
| Enhancing [177Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics J Cheng, J Zink, E O’Neill, B Cornelissen, J Nonnekens, L Livieratos, ... EJNMMI research 14 (1), 73, 2024 | 2 | 2024 |
| Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium JS Israel, LM Marcelin, C Thomas, E Szczyrbová, S Fuessel, M Puhr, ... Journal of Experimental & Clinical Cancer Research 43 (1), 194, 2024 | 2 | 2024 |
| Luminescent Lanthanoid Probes ES O'Neill, EJ New Ligand Design in Medicinal Inorganic Chemistry, 113-143, 2014 | 2 | 2014 |
| Defining the challenges and opportunities for using patient‐derived models in prostate cancer research WN Brennen, C Le Magnen, S Karkampouna, N Anselmino, N Bock, ... The Prostate 84 (7), 623-635, 2024 | 1 | 2024 |
| Imaging PARP with 18F-rucaparib CY Chan, Z Chen, G Destro, M Veal, D Lau, E O’Neill, G Dias, M Mosley, ... Journal of Nuclear Medicine 62 (supplement 1), 1516-1516, 2021 | 1 | 2021 |
| Imaging DNA Damage in vivo following [Lu-177] Lu-DOTATATE therapy in a model of pancreatic neuroendocrine cancer E O'Neill, V Kersemans, P Allen, S Terry, JB Torres, S Smart, BQ Lee, ... EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 46 (SUPPL 1 …, 2019 | 1 | 2019 |
| Evaluation of a synergistic drug combination with 177Lu-rhPSMA-10.1 for prostate cancer: Results of an in vitro screen and in vivo proof of concept study C Foxton, B Cornelissen, E O'Neill, B Waldron, F Pretzmann, RV Grønlund, ... Cancer Research 84 (6_Supplement), 694-694, 2024 | | 2024 |
Bart CornelissenUniversity Medical Centre Groningen / University of OxfordOverená e-mailová adresa na: oncology.ox.ac.uk